JoelWSlatonMD

PubMed

• 3 citations
  Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer.
  Hyun Hwan Sung, Douglas S. Scherr, Joel W. Slaton, Hao Liu, Katy Ledford Feeny, Colleen A. Lingley-Papadopoulos, John Gearheart, Jason M. Zara, Seth P. Lerner> ;Urologic Oncology. 2021 Apr 29
• 26 citations
  Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer
  Needa A. Virani, Carole A. Davis, Patrick McKernan, Paul J. Hauser, Robert E. Hurst, Joel W. Slaton, Ricardo Prada Silvy, Daniel E. Resasco, Roger G. Harrison> ;Nanotechnology. 2018 Jan 19
• 3 citations
  Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer.
  David Muñoz, María Karina Serrano, María Elena Hernández, Ross Haller, Tamara Swanson, Joel W. Slaton, Akhouri A. Sinha, Michael J. Wilson> ;Experimental and Molecular Pathology. 2017 Dec 1
• 9 citations
  Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early st...
  David F. Jarrard, Badrinath R. Konety, Wei Huang, Tracy M. Downs, Jill M. Kolesar, Kyung Mann Kim, Tom Havighurst, Joel W. Slaton, Margaret G. House, Howard L. Parnes,...> ;American Journal of Clinical and Experimental Urology. 2016 Sep 20
• 1 citations
  Disparities in long-term radiographic follow-up after cystectomy for bladder cancer: Analysis of the SEER-Medicare database
  Shaheen Alanee, Sabha Ganai, Priyanka Gupta, Holland Bradley, Danuta Dynda, Joel W. Slaton> ;Urology Annals. 2016 Apr 1
• 12 citations
  Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.
  Janeen H. Trembley, Gretchen M. Unger, Vicci L. Korman, Md. Joynal Abedin, Lucas P. Nacusi, Rachel Isaksson Vogel, Joel W. Slaton, Betsy T. Kren, Khalil Ahmed> ;Plos One. 2014 Oct 15
• 150 citations
  Alvimopan accelerates gastrointestinal recovery after radical cystectomy: A multicenter randomized placebo-controlled trial
  Cheryl T. Lee, Sam S. Chang, Ashish M. Kamat, Gilad E. Amiel, Timothy L. Beard, Amr Fergany, R. Jeffrey Karnes, Andrea Kurz, Venu Menon, Wade J. Sexton, Joel W. Slaton...> ;European Urology. 2014 Aug 1
• 46 citations
  Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, co...
  Teresa L. Kauf, Robert S. Svatek, Gilad E. Amiel, Timothy L. Beard, Sam S. Chang, Amr Fergany, R. Jeffrey Karnes, Michael O. Koch, Jerome F. O'Hara, Cheryl T. Lee, Wad...> ;The Journal of Urology. 2014 Jun 1
• 7 citations
  The risk of bladder cancer in patients diagnosed with other primary neoplasms: analysis of the SEER database
  J. Kyle Anderson, Shaheen Alanee, Bruce R. Lindgren, Joel W. Slaton> ;Urologic Oncology. 2013 Aug 1
• 2 citations
  Contemporary treatment of low risk stage I non-seminomatous germ cell testicular tumors: A survey of the Society of Urologic Oncology
  Shaheen Alanee, Adam Nicholson, Joel W. Slaton> ;Urologic Oncology. 2012 Nov 1
• 17 citations
  Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
  Cynthia A. Wenner, Mark R. Martzen, Hailing Lu, Michael R. Verneris, Hongbo Wang, Joel W. Slaton> ;International Journal of Oncology. 2012 Apr 1
• 11 citations
  Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.
  Nagi B. Kumar, Theresa Crocker, Tiffany Smith, Julio M. Pow-Sang, Philippe E. Spiess, Kathleen Egan, Gwen Quinn, Michael J. Schell, Said M. Sebti, Aslam Kazi, Tian Chu...> ;Contemporary Clinical Trials. 2012 Mar 1
• 33 citations
  Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice
  Janeen H. Trembley, Gretchen M. Unger, Diane K. Tobolt, Vicci L. Korman, Guixia Wang, Kashif A. Ahmad, Joel W. Slaton, Betsy T. Kren, Khalil Ahmed> ;Molecular and Cellular Biochemistry. 2011 Jul 15
• 21 citations
  A three-layer competition-based giant magnetoresistive assay for direct quantification of endoglin from human urine.
  Balasubramanian Srinivasan, Yuanpeng Li, Ying Jing, Chengguo Xing, Joel W. Slaton, Jian-Ping Wang> ;Analytical Chemistry. 2011 Mar 21
• 25 citations
  Role for toll-like receptor 4 in TNF-alpha secretion by murine macrophages in response to polysaccharide Krestin, a Trametes versicolor mushroom extract.
  Lisa A. Price, Cynthia A. Wenner, Daniel T. Sloper, Joel W. Slaton, Jeffrey P. Novack> ;Fitoterapia. 2010 Oct 1
• 25 citations
  Use of Tumor Necrosis Factor–alpha-coated Gold Nanoparticles to Enhance Radiofrequency Ablation in a Translational Model of Renal Tumors
  Renato N. Pedro, Thishore Thekke-Adiyat, Raghav Goel, Mithun M. Shenoi, Joel W. Slaton, Steve Schmechel, John C. Bischof, James Kyle Anderson> ;Urology. 2010 Aug 1
• 152 citations
  Emergence of protein kinase CK2 as a key target in cancer therapy
  Janeen H. Trembley, Zhong Chen, Gretchen M. Unger, Joel W. Slaton, Betsy T. Kren, Carter Van Waes, Khalil Ahmed> ;Biofactors. 2010 May 1
• 40 citations
  Association Between Lymph Node Density and Disease Specific Survival in Patients With Penile Cancer
  Robert S. Svatek, Mark F. Munsell, Jordan M. Kincaid, Paul K. Hegarty, Joel W. Slaton, J. Erik Busby, Kris E. Gaston, Philippe E. Spiess, Lance C. Pagliaro, Pheroze Ta...> ;The Journal of Urology. 2009 Dec 1
• 32 citations
  Adjuvant approaches to enhance cryosurgery.
  Raghav Goel, Kyle Anderson, Joel W. Slaton, Franz Schmidlin, Greg M Vercellotti, John D. Belcher, John C. Bischof> ;Journal of Biomechanical Engineering. 2009 Jul 1
• 267 citations
  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.
  J. H. Trembley, Guixia Wang, Gretchen M. Unger, Joel W. Slaton, Khalil Ahmed> ;Cellular and Molecular Life Sciences. 2009 Apr 24
• 24 citations
  Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP).
  Xing Wang, Michael T. Wilson, Joel W. Slaton, Akhouri A. Sinha, Stephen L. Ewing, Duanqing Pei> ;Journal of Andrology. 2009 May 6
• 39 citations
  Second prize: Comprehensive proteomic analysis of human calcium oxalate monohydrate kidney stone matrix.
  Benjamin K. Canales, Lorraine B. Anderson, LeeAnn Higgins, Joel W. Slaton, Kenneth P. Roberts, Nathan Liu, Manoj Monga> ;Journal of Endourology. 2008 Dec 11
• 26 citations
  WL-276, an Antagonist against Bcl-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth
  Liangyou Wang, Daniel T. Sloper, Sadiya N. Addo, Defeng Tian, Joel W. Slaton, Chengguo Xing> ;Cancer Research. 2008 Jun 1
• 197 citations
  Protein kinase CK2 – A key suppressor of apoptosis
  Kashif A. Ahmad, Guixia Wang, Gretchen M. Unger, Joel W. Slaton, Khalil Ahmed> ;Advances in Enzyme Regulation. 2008 Jan 1
• 33 citations
  Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer.
  Jill M. Hamilton-Reeves, Salome A. Rebello, Will Thomas, Mindy S. Kurzer, Joel W. Slaton> ;Nutrition and Cancer. 2007 Dec 28
• Join now to see all